Many anti-smoking groups and advocates have been opposing electronic cigarettes on the grounds that these products perpetuate or even increase nicotine addiction, rather than decreasing it. But a new study presented at the 2014 annual conference of the Society for Research on Nicotine and Tobacco (SRNT) provides evidence that nicotine addiction levels are actually decreased, not increased, in smokers who have switched to electronic cigarettes.

Instead, the law created a huge bureaucracy full of red tape and sluggish approval processes such that there are still close to 3500 substantial equivalence applications stacked up in a pile somewhere, and the FDA is so overburdened that it cannot even issue electronic cigarette regulations in a reasonable amount of time.

The FDA is essentially saying that ex-smokers who have quit smoking using electronic cigarettes might as well revert back to smoking, since the Agency is not aware that vaping is any less hazardous than smoking. Is this the kind of scientific-based advice that we think is appropriate to be coming from a federal health agency?

Ironically, in the long run, hiding the influence of Big Pharma on smoking cessation policy does not advance the cessation field, but brings it to a grinding halt. The public, and tobacco control practitioners themselves, need to understand the deeply ingrained roots of Big Pharma within the tobacco control movement, especially in the smoking cessation field. Failure to do so will lead to blind following of an industry-based agenda. This is precisely what has happened in tobacco control.

Dr. Benowitz: "Dr. Benowitz, as a paid consultant for pharmaceutical companies, has assisted them with the design, development, and marketing of smoking-cessation products. Among the companies for which he has consulted on such products are GlaxoSmithKline plc and its affiliates (collectively, “GSK”); Pfizer, Inc. and its affiliates (collectively, “Pfizer”); Novartis AG and its affiliates (collectively, “Novartis”); Sanofi-Aventis U.S. LLC and its affiliates (collectively, “Sanofi-Aventis”); and Aradigm Corp. and its affiliates (collectively, “Aradigm”). During the last ten years, he has received at least approximately $10,000 per year for such consulting. He has also received grant support for research and writing from GSK and/or Pfizer on at least five occasions. In 2010, he co-authored a study, funded by Pfizer, on the use of its drug, Chantix, for smoking cessation."

LAST：Electronic ciggarette clearomizer gs h2 ego e cigarette ego clear atomizer GS-H2 cartomizer |NEXT：Shenzhen original factory of electronic cigarette Odeel CE4 Dual Coil Clearomizer